Efficacy of Brincidofovir in Pediatric Stem Cell Transplant Recipients With Adenovirus Infections.
Karoline EhlertJohannes H SchulteJörn-Sven KühlPeter LangAngelika EggertSebastian VoigtPublished in: Journal of the Pediatric Infectious Diseases Society (2021)
AdV DNAemia and intestinal infection subsided completely in 75% of pediatric HSCT recipients treated with BCV. AdV DNAemia exceeding 1 × 109/mL and a poor lymphocyte recovery of <250/µL were associated with high mortality. Early AdV DNAemia before day +21, however, did not result in a worse outcome. Although access to BCV is currently suspended, further clinical trials are needed to clarify the role of BCV in HSCT recipients with AdV infections and its potential benefit in preventing AdV DNAemia in immunocompromised patients.
Keyphrases
- stem cells
- clinical trial
- newly diagnosed
- ejection fraction
- kidney transplantation
- hematopoietic stem cell
- type diabetes
- cardiovascular events
- risk factors
- coronary artery disease
- peripheral blood
- patient reported outcomes
- randomized controlled trial
- mesenchymal stem cells
- intensive care unit
- cardiovascular disease
- bone marrow
- open label
- extracorporeal membrane oxygenation
- double blind
- study protocol
- gene therapy